Sops likely for R&D on rare condition drugs

Incentives could be offered to the private sector in the form of faster approvals and an extended period of exclusivity for orphan drugs. Since only a small population of patients is affected by these rare conditions and so needs such drugs, it is often not profitable enough for the private sector to venture into them without government support.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zPSHlJj
via IFTTT